Natural Killer Cells

[Cell Reports] The authors demonstrated the applicability of high-content imaging to human T and natural killer cells and develop a pipeline for unbiased analysis of high-definition morphological profiles.

[Abcuro, Inc.] Abcuro, Inc. and ImaginAb shared initial results of a study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis, an autoimmune disease in which cytotoxic CD8+ T cells chronically attack muscle cells, leading to progressive weakness and severe disability.

[XNK Therapeutics AB] XNK Therapeutics AB announced that the first patient has been included in a Phase II clinical study to treat patients with multiple myeloma using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.

[Human Genomics] Scientists used the commercial Chromium platform to perform sc-ATAC-seq to measure chromatin accessibility in 11,611 single umbilical cord blood cells derived from one trisomy 18 syndrome patient and one healthy donor.

[Journal of Clinical Investigation] Mechanistically, scientists demonstrated that NK cell degranulation is mediated by binding of the Fc segment of anti-RhD antibodies to CD16, the main Fcγ receptor expressed on NK cells.

[Proceedings of the National Academy of Sciences of the United States of America] Using different preclinical models for liver metastasis, researchers found that tissue-resident type I innate lymphoid cells controlled metastatic seeding, whereas conventional NKs restrain outgrowth.